West Pharmaceutical Services Inc. (WST) reported $3.40B of revenue for the twelve months ended Sep 30, 2026. That is up 12.6% from the year before. Revenue for fiscal 2025 was $3.07B.

Yes. West Pharmaceutical Services Inc. earned $638.90M in net income for the twelve months ended Sep 30, 2026, a net margin of 18.8%.

How much cash and debt does WST have?

West Pharmaceutical Services Inc. reported $464.10M in cash and cash equivalents and $202.90M of debt on its most recent balance sheet in SEC filings.

How fast is WST revenue growing?

West Pharmaceutical Services Inc.'s revenue changed +6.3% in fiscal 2025, to $3.07B. Its compound annual growth rate was +7.4% over 5 years and +8.2% over 10 years.

What is WST gross margin?

West Pharmaceutical Services Inc.'s gross profit was $1.28B on $3.40B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 37.6%.

What is WST free cash flow?

West Pharmaceutical Services Inc. generated $453.40M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $654.50M less capital expenditures.

What is WST earnings per share?

Diluted earnings per share were $8.91 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did WST last report financial results?

The latest statements here come from West Pharmaceutical Services Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.

Financials · WST

West Pharmaceutical Services Inc. (WST) financials

For the twelve months ended Sep 30, 2026, West Pharmaceutical Services Inc. reported $3.40B of revenue and $638.90M of net income.

Revenue, TTM: $3.40B
Revenue growth, YoY: +12.6%
Net income, TTM: $638.90M
Net income growth, YoY: +29.9%
Net margin: 18.8%
Free cash flow, TTM: $453.40M
EPS, diluted, TTM: $8.91
EPS growth, YoY: +32.0%
Cash: $464.10M
Total debt: $202.90M
P/E: 43.59
P/S: 8.20
Market cap: $27.85B

Annual revenue$3.07B

FY2016FY2025

Annual net income$493.70M

FY2016FY2025

Annual free cash flow$468.90M

FY2016FY2025

WST revenue and earnings growth

WST revenueQ3 2026$874.50M

Quarter YoY: +8.7%
QoQ: +0.3%
FY YoY: +6.3%
5Y CAGR: +7.4%
10Y CAGR: +8.2%

WST revenue was $874.50M in fiscal Q3 2026 (ended Sep 30, 2026), up 8.7% from a year earlier and up 0.3% from the prior quarter. For the full fiscal 2025 it was $3.07B, up 6.3% from fiscal 2024. Compound annual growth was +7.4% over 5 years and +8.2% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

WST net incomeQ3 2026$214.00M

Quarter YoY: +52.9%
QoQ: +39.0%
FY YoY: +0.2%
5Y CAGR: +7.4%
10Y CAGR: +17.8%

WST net income was $214.00M in fiscal Q3 2026 (ended Sep 30, 2026), up 52.9% from a year earlier and up 39.0% from the prior quarter. For the full fiscal 2025 it was $493.70M, up 0.2% from fiscal 2024. Compound annual growth was +7.4% over 5 years and +17.8% over 10 years. It rose in 8 of the last 10 fiscal years.

WST EPSQ3 2026$3.02

Quarter YoY: +57.3%
QoQ: +40.5%
FY YoY: +1.5%
5Y CAGR: +8.2%
10Y CAGR: +18.0%

WST diluted EPS was $3.02 in fiscal Q3 2026 (ended Sep 30, 2026), up 57.3% from a year earlier and up 40.5% from the prior quarter. For the full fiscal 2025 it was $6.79, up 1.5% from fiscal 2024. Compound annual growth was +8.2% over 5 years and +18.0% over 10 years.

WST free cash flowQ3 2026$150.40M

Quarter YoY: +12.3%
QoQ: +86.1%
FY YoY: +69.6%
5Y CAGR: +9.5%
10Y CAGR: +19.2%

WST free cash flow was $150.40M in fiscal Q3 2026 (ended Sep 30, 2026), up 12.3% from a year earlier and up 86.1% from the prior quarter. For the full fiscal 2025 it was $468.90M, up 69.6% from fiscal 2024. Compound annual growth was +9.5% over 5 years and +19.2% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$3.07B	$2.89B	$2.95B	$2.89B	$2.83B	$2.15B	$1.84B	$1.72B	$1.60B	$1.51B
Cost of revenue	$1.97B	$1.89B	$1.82B	$1.75B	$1.66B	$1.38B	$1.23B	$1.17B	$1.09B	$1.01B
Gross profit	$1.10B	$998.50M	$1.13B	$1.14B	$1.18B	$767.80M	$605.70M	$545.40M	$512.90M	$501.40M
Research and development	$74.30M	$69.10M	$68.40M	$58.50M	$52.80M	$46.90M	$38.90M	$40.30M	$39.10M	$36.80M
Selling, general and admin	$393.60M	$338.50M	$353.40M	$316.90M	$362.80M	$302.00M	$272.70M	$262.90M	$246.00M	$239.60M
Operating income	$584.90M	$569.90M	$676.00M	$734.00M	$752.30M	$406.90M	$296.60M	$240.30M	$225.80M	$195.20M
Interest expense	$500.0K	$3.00M	$9.00M	$7.90M	$8.20M	$8.20M	$8.50M	$8.40M	$7.80M	$8.10M
Pre-tax income	$600.90M	$585.50M	$698.00M	$679.90M	$748.90M	$401.30M	$291.80M	$240.70M	$222.40M	$189.80M
Income tax	$121.60M	$107.50M	$122.30M	$114.70M	$107.20M	$72.50M	$59.00M	$41.40M	$80.90M	$54.40M
Net income	$493.70M	$492.70M	$593.40M	$585.90M	$661.80M	$346.20M	$241.70M	$206.90M	$150.70M	$143.60M
EPS, basic	$6.83	$6.75	$7.98	$7.87	$8.89	$4.68	$3.27	$2.80	$2.04	$1.96
EPS, diluted	$6.79	$6.69	$7.88	$7.73	$8.67	$4.57	$3.21	$2.74	$1.99	$1.91
Diluted shares	72.7M	73.7M	75.3M	75.8M	76.3M	75.8M	75.4M	75.4M	75.8M	75.0M

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$791.30M	$484.60M	$853.90M	$894.30M	$762.60M	$615.50M	$439.10M	$337.40M	$235.90M	$203.00M
Receivables	$574.40M	$552.50M	$512.00M	$507.40M	$489.00M	$385.30M	$319.30M	$288.20M	$253.20M	$200.50M
Inventory	$443.90M	$377.00M	$434.70M	$414.80M	$378.40M	$321.30M	$235.70M	$214.50M	$215.20M	$199.30M
Current assets	$1.98B	$1.54B	$1.94B	$1.92B	$1.74B	$1.37B	$1.06B	$894.40M	$743.50M	$641.90M
Goodwill	$109.90M	$106.00M	$108.50M	$107.30M	$109.90M	$111.10M	$107.80M	$105.80M	$107.70M	$103.00M
Total assets	$4.27B	$3.64B	$3.83B	$3.62B	$3.31B	$2.79B	$2.34B	$1.98B	$1.86B	$1.72B
Current liabilities	$654.90M	$550.40M	$671.80M	$519.00M	$594.10M	$503.40M	$341.60M	$283.70M	$279.50M	$241.00M
Short-term debt	$0	$0	$134.00M	$2.20M	$44.20M	$2.30M	$2.30M	$100.0K	$0	$2.40M
Long-term debt	$202.80M	$202.60M	$72.80M	$206.70M	$208.80M	$252.90M	$255.00M	$196.00M	$197.00M	$226.20M
Total debt	$202.80M	$202.60M	$206.80M	$208.90M	$253.00M	$255.20M	$257.30M	$196.10M	$197.00M	$228.60M
Total liabilities	$1.09B	$961.10M	$948.50M	$931.90M	$978.40M	$939.30M	$768.20M	$582.60M	$582.90M	$599.20M
Shareholders' equity	$3.18B	$2.68B	$2.88B	$2.68B	$2.34B	$1.85B	$1.57B	$1.40B	$1.28B	$1.12B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$754.80M	$653.40M	$776.50M	$724.00M	$584.00M	$472.50M	$367.20M	$288.60M	$263.30M	$219.40M
Capital expenditures	$285.90M	$377.00M	$362.00M	$284.60M	$253.40M	$174.40M	$126.40M	$104.70M	$130.80M	$170.20M
Free cash flow	$468.90M	$276.40M	$414.50M	$439.40M	$330.60M	$298.10M	$240.80M	$183.90M	$132.50M	$49.20M
Investing cash flow	-$285.90M	-$378.70M	-$368.70M	-$288.20M	-$253.10M	-$179.50M	-$228.00M	-$100.80M	-$133.60M	-$175.80M
Financing cash flow	-$185.10M	-$622.60M	-$459.60M	-$293.60M	-$168.10M	-$137.10M	-$36.80M	-$80.70M	-$109.00M	-$113.90M
Dividends paid	$61.20M	$59.10M	$57.00M	$54.10M	$51.10M	$48.10M	$45.10M	$42.10M	$39.10M	$35.80M
Share repurchases	$134.00M	$560.90M	$438.30M	$202.80M	$137.10M	$115.50M	$83.10M	$70.80M	$74.40M	$52.20M
Stock-based compensation	$23.80M	$18.70M	$23.30M	$23.70M	$37.50M	$34.00M	$24.40M	$15.10M	$16.10M	$19.50M
Depreciation and amortization	$171.40M	$155.40M	$137.30M	$120.60M	$122.30M	$109.10M	$103.40M	$104.40M	$96.70M	$90.70M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	6.3%	-1.9%	2.2%	2.0%	31.9%	16.7%	7.1%	7.4%	6.0%	7.8%
Net income growth, YoY	0.2%	-17.0%	1.3%	-11.5%	91.2%	43.2%	16.8%	37.3%	4.9%	50.2%
EPS growth, YoY	1.5%	-15.1%	1.9%	-10.8%	89.7%	42.4%	17.2%	37.7%	4.2%	46.9%
Gross margin	35.9%	34.5%	38.3%	39.4%	41.5%	35.8%	32.9%	31.8%	32.1%	33.2%
Operating margin	19.0%	19.7%	22.9%	25.4%	26.6%	19.0%	16.1%	14.0%	14.1%	12.9%
Net margin	16.1%	17.0%	20.1%	20.3%	23.4%	16.1%	13.1%	12.0%	9.4%	9.5%
Free cash flow margin	15.3%	9.6%	14.1%	15.2%	11.7%	13.9%	13.1%	10.7%	8.3%	3.3%
Return on equity	15.5%	18.4%	20.6%	21.8%	28.3%	18.7%	15.4%	14.8%	11.8%	12.9%
Return on assets	11.6%	13.5%	15.5%	16.2%	20.0%	12.4%	10.3%	10.5%	8.1%	8.4%
Current ratio	3.02	2.79	2.88	3.70	2.93	2.73	3.10	3.15	2.66	2.66
Debt to equity	0.06	0.08	0.07	0.08	0.11	0.14	0.16	0.14	0.15	0.20

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue	$874.50M	$872.30M	$844.90M	$805.00M	$804.60M	$766.50M	$698.00M	$748.80M	$746.90M	$702.10M	$695.40M	$732.00M
Cost of revenue	$527.10M	$543.10M	$548.50M	$501.10M	$510.30M	$492.60M	$466.10M	$475.20M	$482.20M	$472.10M	$465.20M	$453.80M
Gross profit	$347.40M	$329.20M	$296.40M	$303.90M	$294.30M	$273.90M	$231.90M	$273.60M	$264.70M	$230.00M	$230.20M	$278.20M
Research and development	$18.30M	$19.70M	$15.80M	$21.80M	$17.10M	$19.10M	$16.30M	$18.50M	$15.50M	$17.50M	$17.60M	$18.40M
Selling, general and admin	$112.90M	$117.60M	$99.50M	$107.00M	$102.70M	$95.90M	$88.00M	$85.30M	$83.50M	$83.00M	$86.70M	$90.00M
Operating income	$267.40M	$179.10M	$177.10M	$156.60M	$167.60M	$153.70M	$107.00M	$159.60M	$161.30M	$126.20M	$122.80M	$160.90M
Interest expense	$3.80M	$2.60M	$1.90M	-$200.0K	$200.0K	$100.0K	$400.0K	-$800.0K	$700.0K	$1.50M	$1.60M	$1.20M
Pre-tax income	$267.70M	$180.10M	$180.10M	$161.50M	$171.90M	$157.00M	$110.50M	$164.90M	$164.50M	$128.70M	$127.40M	$168.20M
Income tax	$58.00M	$32.20M	$44.70M	$33.30M	$34.00M	$30.20M	$24.10M	$36.80M	$32.40M	$21.90M	$16.40M	$34.50M
Net income	$214.00M	$154.00M	$138.80M	$132.10M	$140.00M	$131.80M	$89.80M	$130.10M	$136.00M	$111.30M	$115.30M	$137.00M
EPS, basic	$3.04	$2.17	$1.93	$1.83	$1.94	$1.82	$1.24	$1.79	$1.87	$1.52	$1.57	$1.85
EPS, diluted	$3.02	$2.15	$1.92	$1.82	$1.92	$1.82	$1.23	$1.78	$1.85	$1.51	$1.55	$1.83
Diluted shares	70.8M	71.3M	72.4M	-	72.6M	72.5M	73.0M	-	73.4M	73.7M	74.3M	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Cash and equivalents	$464.10M	$435.80M	$521.40M	$791.30M	$628.50M	$509.70M	$404.20M	$484.60M	$490.90M	$446.20M	$601.80M	$853.90M
Receivables	$748.20M	$712.00M	$685.60M	$574.40M	$625.00M	$582.40M	$543.60M	$552.50M	$524.30M	$479.40M	$524.00M	$512.00M
Inventory	$464.70M	$447.40M	$452.60M	$443.90M	$438.00M	$421.10M	$388.70M	$377.00M	$401.20M	$419.20M	$429.90M	$434.70M
Current assets	$1.82B	$1.81B	$1.83B	$1.98B	$1.82B	$1.68B	$1.46B	$1.54B	$1.55B	$1.48B	$1.69B	$1.94B
Goodwill	$108.70M	$108.70M	$109.20M	$109.90M	$110.60M	$110.90M	$107.50M	$106.00M	$108.80M	$107.30M	$107.60M	$108.50M
Total assets	$4.06B	$4.08B	$4.11B	$4.27B	$4.11B	$3.95B	$3.62B	$3.64B	$3.68B	$3.49B	$3.60B	$3.83B
Current liabilities	$644.30M	$640.50M	$674.00M	$654.90M	$635.40M	$604.60M	$526.70M	$550.40M	$516.50M	$633.70M	$648.40M	$671.80M
Short-term debt	$0	$0	$0	$0	$0	$0	$0	$0	$0	$132.90M	$133.40M	$134.00M
Long-term debt	$202.90M	$202.90M	$202.80M	$202.80M	$202.70M	$202.60M	$202.60M	$202.60M	$202.60M	$72.90M	$72.80M	$72.80M
Total debt	$202.90M	$202.90M	$202.80M	$202.80M	$202.70M	$202.60M	$202.60M	$202.60M	$202.60M	$205.80M	$206.20M	$206.80M
Total liabilities	$1.09B	$1.09B	$1.12B	$1.09B	$1.05B	$1.02B	$935.10M	$961.10M	$923.00M	$912.60M	$921.70M	$948.50M
Shareholders' equity	$2.97B	$2.99B	$2.99B	$3.18B	$3.05B	$2.93B	$2.68B	$2.68B	$2.75B	$2.58B	$2.68B	$2.88B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Operating cash flow	$189.50M	$124.00M	$89.90M	$251.10M	$197.20M	$177.10M	$129.40M	$190.10M	$180.10M	$165.00M	$118.20M	$239.10M
Capital expenditures	$39.10M	$43.20M	$42.70M	$76.10M	$63.30M	$75.20M	$71.30M	$104.90M	$81.30M	$100.20M	$90.60M	$108.70M
Free cash flow	$150.40M	$80.80M	$47.20M	$175.00M	$133.90M	$101.90M	$58.10M	$85.20M	$98.80M	$64.80M	$27.60M	$130.40M
Investing cash flow	$78.90M	-$43.20M	-$42.70M	-$76.10M	-$63.30M	-$75.20M	-$71.30M	-$104.80M	-$82.10M	-$101.20M	-$90.60M	-$108.80M
Financing cash flow	-$241.80M	-$164.80M	-$308.70M	-$11.70M	-$11.50M	-$14.90M	-$147.00M	-$68.90M	-$64.40M	-$218.30M	-$271.00M	-$189.50M
Dividends paid	$15.50M	$15.70M	$15.80M	$15.80M	$15.10M	$15.10M	$15.20M	$15.30M	$14.50M	$14.60M	$14.70M	$14.80M
Share repurchases	$231.00M	$156.70M	$297.60M	$0	$0	$500.0K	$133.50M	$54.40M	$52.40M	$187.10M	$267.00M	$177.00M
Stock-based compensation	$4.30M	$10.90M	$6.60M	$6.70M	$8.40M	$7.40M	$1.30M	$4.30M	$5.10M	$4.30M	$5.00M	$1.40M
Depreciation and amortization	$45.90M	$46.20M	$45.20M	$47.00M	$43.00M	$41.40M	$40.00M	$40.70M	$40.20M	$38.90M	$35.60M	-

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025* Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024* Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023* Dec 31, 2023
Revenue growth, YoY	8.7%	13.8%	21.0%	7.5%	7.7%	9.2%	0.4%	2.3%	-0.1%	-6.9%	-3.0%	3.3%
Net income growth, YoY	52.9%	16.8%	54.6%	1.5%	2.9%	18.4%	-22.1%	-5.0%	-15.7%	-28.2%	-17.6%	33.0%
EPS growth, YoY	57.3%	18.1%	56.1%	2.2%	3.8%	20.5%	-20.6%	-2.7%	-13.6%	-26.7%	-16.2%	33.6%
Gross margin	39.7%	37.7%	35.1%	37.8%	36.6%	35.7%	33.2%	36.5%	35.4%	32.8%	33.1%	38.0%
Operating margin	30.6%	20.5%	21.0%	19.5%	20.8%	20.1%	15.3%	21.3%	21.6%	18.0%	17.7%	22.0%
Net margin	24.5%	17.7%	16.4%	16.4%	17.4%	17.2%	12.9%	17.4%	18.2%	15.9%	16.6%	18.7%
Free cash flow margin	17.2%	9.3%	5.6%	21.7%	16.6%	13.3%	8.3%	11.4%	13.2%	9.2%	4.0%	17.8%
Current ratio	2.82	2.82	2.71	3.02	2.87	2.78	2.77	2.79	3.00	2.34	2.61	2.88
Debt to equity	0.07	0.07	0.07	0.06	0.07	0.07	0.08	0.08	0.07	0.08	0.08	0.07

Source: XBRL data West Pharmaceutical Services Inc. files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Nov 4, 2013.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

WST peers

Company	Revenue	Growth	Net income	Net margin	Market cap
WST	$3.40B	+12.6%	$638.90M	18.8%	$27.85B
SYKStryker Corporation	$26.30B	+7.9%	$3.62B	13.8%	$124.05B
MMM3M Company	$25.25B	+1.7%	$3.54B	14.0%	$95.67B
BSXBoston Scientific Corporation	$21.07B	+8.9%	$3.50B	16.6%	$61.96B
BDXBecton Dickinson and Company	$23.25B	+17.4%	$941.00M	4.0%	$57.71B
MDLNMedline Inc.	$30.68B	-	$683.00M	2.2%	$52.13B
RMDResMed Inc.	$5.73B	+9.0%	$1.59B	27.8%	$33.10B
DXCMDexCom Inc.	$5.10B	+13.0%	$991.00M	19.4%	$29.62B
SOLVSolventum Corporation	$8.16B	-2.8%	$156.00M	1.9%	$15.38B

WST FAQ

9 questions

What is WST revenue?
West Pharmaceutical Services Inc. (WST) reported $3.40B of revenue for the twelve months ended Sep 30, 2026. That is up 12.6% from the year before. Revenue for fiscal 2025 was $3.07B.
Is WST profitable?
Yes. West Pharmaceutical Services Inc. earned $638.90M in net income for the twelve months ended Sep 30, 2026, a net margin of 18.8%.
How much cash and debt does WST have?
West Pharmaceutical Services Inc. reported $464.10M in cash and cash equivalents and $202.90M of debt on its most recent balance sheet in SEC filings.
How fast is WST revenue growing?
West Pharmaceutical Services Inc.'s revenue changed +6.3% in fiscal 2025, to $3.07B. Its compound annual growth rate was +7.4% over 5 years and +8.2% over 10 years.
What is WST gross margin?
West Pharmaceutical Services Inc.'s gross profit was $1.28B on $3.40B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 37.6%.
What is WST free cash flow?
West Pharmaceutical Services Inc. generated $453.40M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $654.50M less capital expenditures.
What is WST earnings per share?
Diluted earnings per share were $8.91 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did WST last report financial results?
The latest statements here come from West Pharmaceutical Services Inc.'s 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
Where does this WST financial data come from?
Quantisnow builds these statements from the structured XBRL data West Pharmaceutical Services Inc. files with the SEC. It is provided for information only and is not investment advice.